Fruquintinib plus sintilimab in previously bevacizumab-treated, pMMR/MSS refractory metastatic colorectal cancer: a phase 2 clinical trial.

ABSTRACT:

Background

This study aimed to investigate the efficacy and safety of fruquintinib plus sintilimab in mismatch repair-proficient (pMMR)/microstatellite stable (MSS) refractory metastatic colorectal cancer (mCRC).

Methods

Patients with pMMR/MSS mCRCs who had failed at least 2 lines of standard therapy were enrolled and treated with fruquintinib plus sintilimab in this single arm, phase II clinical trial. The primary endpoint was the 6 month progression-free survival (PFS) rate.

Results

A total of 75 patients were included, all of whom had been previously treated with bevacizumab. The 6 month PFS rate was 33.3%. The median PFS (mPFS) was 4.1 months, the median overall survival (mOS) was 15.3 months, the objective response rate (ORR) was 12.5%, and the disease control ra

SUBMITTER: Zhang W 

PROVIDER: S-EPMC12635018 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature